Vacuolar ATPase as a possible therapeutic target in human acute myeloid leukemia

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20);2391–2405.
   PubMed Web of Science ®Google Scholar
• Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–447.
   PubMed Web of Science ®Google Scholar
• Stein EM, DiNardo CD, Pollyea DA, et al. Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia. Blood. 2017;130(6):722–731.
   PubMed Web of Science ®Google Scholar
• Pemmaraju N, Kantarjian H, Garcia-Manero G, et al. Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experience. Am J Hematol. 2015;90(1):27–30.
   PubMed Web of Science ®Google Scholar
• Stransky L, Cotter K, Forgac M. The function of V-ATPases in cancer. Physiol Rev. 2016;96(3):1071–1091.
   PubMed Web of Science ®Google Scholar
• Spugnini EP, Sonveaux P, Stock C, et al. Proton channels and exchangers in cancer. Biochim Biophys Acta. 2015;1848(10 Pt B):2715–2726.
   PubMed Web of Science ®Google Scholar
• Lee YY, Jeon HK, Hong JE, et al. Proton pump inhibitors enhance the effects of cytotoxic agents in chemoresistant epithelial ovarian carcinoma. Oncotarget. 2015;6(33):35040–35050.
   PubMed Web of Science ®Google Scholar
• Fan S, Niu Y, Tan N, et al. LASS2 enhances chemosensitivity of breast cancer by counteracting acidic tumor microenvironment through inhibiting activity of V-ATPase proton pump. Oncogene. 2013;32(13):1682–1690.
   PubMed Web of Science ®Google Scholar
• Graham RM, Thompson JW, Webster KA. Inhibition of the vacuolar ATPase induces Bnip3-dependent death of cancer cells and a reduction in tumor burden and metastasis. Oncotarget. 2014;5(5):1162–1173.
   PubMed Web of Science ®Google Scholar
• Hamm R, Zeino M, Frewert S, et al. Up-regulation of cholesterol associated genes as novel resistance mechanism in glioblastoma cells in response to archazolid B. Toxicol Appl Pharmacol. 2014;281(1):78–86.
   PubMed Web of Science ®Google Scholar
• Zhao J, Benlekbir S, Rubinstein JL. Electron cryomicroscopy observation of rotational states in a eukaryotic V-ATPase. Nature. 2015;521(7551):241–245.
   PubMed Web of Science ®Google Scholar
• Couoh-Cardel S, Milgrom E, Wilkens S. Affinity purification and structural features of the yeast vacuolar ATPase vo membrane sector. J Biol Chem. 2015;290(46):27959–27971.
   PubMed Web of Science ®Google Scholar
• Mazhab-Jafari MT, Rohou A, Schmidt C, et al. Atomic model for the membrane-embedded VO motor of a eukaryotic V-ATPase. Nature. 2016;539(7627):118–122.
   PubMed Web of Science ®Google Scholar
• Merkulova M, Paunescu TG, Azroyan A, et al. Mapping the H(+) (V)-ATPase interactome: identification of proteins involved in trafficking, folding, assembly and phosphorylation. Sci Rep. 2015;5:14827.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Tvedt TH, Nepstad I, et al. Patients with acute myeloid leukemia can be subclassified based on the constitutive cytokine release of the leukemic cells; the possible clinical relevance and the importance of cellular iron metabolism. Expert Opin Ther Targets. 2017;21(4):357–369.
   PubMed Web of Science ®Google Scholar
• Honnemyr M, Bruserud Ø, Brenner AK. The constitutive protease release by primary human acute myeloid leukemia cells. J Cancer Res Clin Oncol. 2017;143(10):1985–1998.
   PubMed Web of Science ®Google Scholar
• Hartl FU, Hayer-Hartl M. Molecular chaperones in the cytosol: from nascent chain to folded protein. Science. 2002;295(5561):1852–1858.
   PubMed Web of Science ®Google Scholar
• Roh SH, Kasembeli M, Bakthavatsalam D, et al. Contribution of the Type II Chaperonin, TRiC/CCT, to Oncogenesis. Int J Mol Sci. 2015;16(11):26706–26720.
   PubMed Web of Science ®Google Scholar
• Lopez T, Dalton K, Frydman J. The mechanism and function of Group II chaperonins. J Mol Biol. 2015;427(18):2919–2930.
   PubMed Web of Science ®Google Scholar
• Roh SH, Kasembeli M, Galaz-Montoya JG, et al. Chaperonin TRiC/CCT modulates the folding and activity of leukemogenic fusion oncoprotein AML1-ETO. J Biol Chem. 2016;291(9):4732–4741.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Nepstad I, Hauge M, et al. STAT3 as a possible therapeutic target in human malignancies: lessons from acute myeloid leukemia. Expert Rev Hematol. 2015;8(1):29–41.
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Bedringsaas SL, Ryningen A, et al. Hypoxia increases HIF-1alpha expression and constitutive cytokine release by primary human acute myeloid leukaemia cells. Eur Cytokine Netw. 2010;21(3):154–164.
   PubMed Web of Science ®Google Scholar
• Anensen N, Hjelle SM, Van Belle W, et al. Correlation analysis of p53 protein isoforms with NPM1/FLT3 mutations and therapy response in acute myeloid leukemia. Oncogene. 2012;31(12):1533–1545.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Reikvam H, Lavecchia A, et al. Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia–the possibility to target several kinases through inhibition of the various CDC25 isoforms. Molecules. 2014;19(11):18414–18447.
   PubMed Web of Science ®Google Scholar
• Konopleva M, Milella M, Ruvolo P, et al. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex. Leukemia. 2012;26(4):778–787.
   PubMed Web of Science ®Google Scholar
• Wermke M, Camgoz A, Paszkowski-Rogacz M, et al. RNAi profiling of primary human AML cells identifies ROCK1 as a therapeutic target and nominates fasudil as an antileukemic drug. Blood. 2015;125(24):3760–3768.
   PubMed Web of Science ®Google Scholar
• Salem M, Delwel R, Touw I, et al. Human AML colony growth in serum-free culture. Leuk Res. 1988;12(2):157–165.
   PubMed Web of Science ®Google Scholar
• Paolillo R, Spinello I, Mt Q, et al. Human TM9SF4 is a new gene down-regulated by hypoxia and involved in cell adhesion of leukemic cells. PLoS One. 2015;10(5):e0126968.
   PubMed Web of Science ®Google Scholar
• Bernhard SM, Seidel K, Schmitz J, et al. The (pro)renin receptor ((P)RR) can act as a repressor of Wnt signalling. Biochem Pharmacol. 2012;84(12):1643–1650.
   PubMed Web of Science ®Google Scholar
• Pamarthy S, Jaiswal MK, Kulshreshtha A, et al. The Vacuolar ATPase a2-subunit regulates Notch signaling in triple-negative breast cancer cells. Oncotarget. 2015;6(33):34206–34220.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Andersson Tvedt TH, Bruserud Ø. The complexity of targeting PI3K-Akt-mTOR signalling in human acute myeloid leukaemia: the importance of leukemic cell heterogeneity, neighbouring mesenchymal stem cells and immunocompetent cells. Molecules. 2016;21(11):1512.
   PubMed Web of Science ®Google Scholar
• Stransky LA, Forgac M. Amino acid availability modulates vacuolar H+-ATPase assembly. J Biol Chem. 2015;290(45):27360–27369.
   PubMed Web of Science ®Google Scholar
• Sharma M, Astekar M, Soi S, et al. pH gradient reversal: an emerging hallmark of cancers. Recent Pat Anticancer Drug Discov. 2015;10(3):244–258.
   PubMed Web of Science ®Google Scholar
• Webb BA, Chimenti M, Jacobson MP, et al. Dysregulated pH: a perfect storm for cancer progression. Nat Rev Cancer. 2011;11(9):671–677.
   PubMed Web of Science ®Google Scholar
• De Milito A, Canese R, Marino ML, et al. pH-dependent antitumor activity of proton pump inhibitors against human melanoma is mediated by inhibition of tumor acidity. Int J Cancer. 2010;127(1):207–219.
   PubMed Web of Science ®Google Scholar
• Marino ML, Fais S, Djavaheri-Mergny M, et al. Proton pump inhibition induces autophagy as a survival mechanism following oxidative stress in human melanoma cells. Cell Death Dis. 2010;1:e87.
   PubMed Web of Science ®Google Scholar
• Von Schwarzenberg K, Wiedmann RM, Oak P, et al. Mode of cell death induction by pharmacological vacuolar H+-ATPase (V-ATPase) inhibition. J Biol Chem. 2013;288(2):1385–1396.
   PubMed Web of Science ®Google Scholar
• Horova V, Hradilova N, Jelinkova I, et al. Inhibition of vacuolar ATPase attenuates the TRAIL-induced activation of caspase-8 and modulates the trafficking of TRAIL receptosomes. Febs J. 2013;280(14):3436–3450.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hauge M, Brenner AK, et al. Emerging therapeutic targets for the treatment of human acute myeloid leukemia (part 1) - gene transcription, cell cycle regulation, metabolism and intercellular communication. Expert Rev Hematol. 2015;8(3):299–313.
   PubMed Web of Science ®Google Scholar
• Tvedt TH, Nepstad I, Bruserud Ø. Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells. Expert Opin Investig Drugs. 2017;26(3):343–355.
   PubMed Web of Science ®Google Scholar
• Brenner AK, Reikvam H, Bruserud Ø. A subset of patients with acute myeloid leukemia has leukemia cells characterized by chemokine responsiveness and altered expression of transcriptional as well as angiogenic regulators. Front Immunol. 2016;7:205.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Brenner AK, Hagen KM, et al. The cytokine-mediated crosstalk between primary human acute myeloid cells and mesenchymal stem cells alters the local cytokine network and the global gene expression profile of the mesenchymal cells. Stem Cell Res. 2015;15(3):530–541.
   PubMed Web of Science ®Google Scholar
• Lynch JR, Wang JY. G protein-coupled receptor signaling in stem cells and cancer. Int J Mol Sci. 2016;17(5):707.
   Web of Science ®Google Scholar
• Brenner AK, Nepstad I, Bruserud Ø. Mesenchymal stem cells support survival and proliferation of primary human acute myeloid leukemia cells through heterogeneous molecular mechanisms. Front Immunol. 2017;8:106.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Aasebø E, Hernandez-Valladares M, et al. Therapeutic targeting of leukemic stem cells in acute myeloid leukemia - the biological background for possible strategies. Expert Opin Drug Discov. 2017;12(10):1053–1065.
   PubMed Web of Science ®Google Scholar
• Zhou HS, Carter BZ, Andreeff M. Bone marrow niche-mediated survival of leukemia stem cells in acute myeloid leukemia: Yin and Yang. Cancer Biol Med. 2016;13(2):248–259.
   PubMed Web of Science ®Google Scholar
• Sadras T, Perugini M, Kok CH, et al. Interleukin-3-mediated regulation of beta-catenin in myeloid transformation and acute myeloid leukemia. J Leukoc Biol. 2014;96(1):83–91.
   PubMed Web of Science ®Google Scholar
• Despeaux M, Chicanne G, Rouer E, et al. Focal adhesion kinase splice variants maintain primitive acute myeloid leukemia cells through altered Wnt signaling. Stem Cells. 2012;30(8):1597–1610.
   PubMed Web of Science ®Google Scholar
• Kuhn K, Cott C, Bohler S, et al. The interplay of autophagy and beta-Catenin signaling regulates differentiation in acute myeloid leukemia. Cell Death Discov. 2015;1:15031.
   PubMedGoogle Scholar
• Griffiths EA, Golding MC, Srivastava P, et al. Pharmacological targeting of beta-catenin in normal karyotype acute myeloid leukemia blasts. Haematologica. 2015;100(2):e49–52.
   PubMed Web of Science ®Google Scholar
• Lobry C, Oh P, Mansour MR, et al. Notch signaling: switching an oncogene to a tumor suppressor. Blood. 2014;123(16):2451–2459.
   PubMed Web of Science ®Google Scholar
• Kannan S, Sutphin RM, Hall MG, et al. Notch activation inhibits AML growth and survival: a potential therapeutic approach. J Exp Med. 2013;210(2):321–337.
   PubMed Web of Science ®Google Scholar
• Lobry C, Ntziachristos P, Ndiaye-Lobry D, et al. Notch pathway activation targets AML-initiating cell homeostasis and differentiation. J Exp Med. 2013;210(2):301–319.
   PubMed Web of Science ®Google Scholar
• Takam Kamga P, Bassi G, Cassaro A, et al. Notch signalling drives bone marrow stromal cell-mediated chemoresistance in acute myeloid leukemia. Oncotarget. 2016;7(16):21713–21727.
   PubMed Web of Science ®Google Scholar
• Zhang J, Ye J, Ma D, et al. Cross-talk between leukemic and endothelial cells promotes angiogenesis by VEGF activation of the Notch/Dll4 pathway. Carcinogenesis. 2013;34(3):667–677.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Tamburini J, Skrede S, et al. Antileukaemic effect of PI3K-mTOR inhibitors in acute myeloid leukaemia-gene expression profiles reveal CDC25B expression as determinate of pharmacological effect. Br J Haematol. 2014;164(2):200–211.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Nepstad I, Bruserud Ø, et al. Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells. Oncotarget. 2013;4(6):830–843.
   PubMed Web of Science ®Google Scholar
• Xie C, He Y, Zhen M, et al. Puquitinib, a novel orally available PI3Kdelta inhibitor, exhibits potent antitumor efficacy against acute myeloid leukemia. Cancer Sci. 2017;108(7):1476–1484.
   PubMed Web of Science ®Google Scholar
• Ragon BK, Kantarjian H, Jabbour E, et al. Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 2017;92(1):7–11.
   PubMed Web of Science ®Google Scholar
• Tan P, Tiong IS, Fleming S, et al. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study. Oncotarget. 2017;8(32):52269–52280.
   PubMed Web of Science ®Google Scholar
• Zeng Z, Liu W, Tsao T, et al. High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia. Haematologica. 2017;102(9):1537–1548.
   PubMed Web of Science ®Google Scholar
• Aasebo E, Vaudel M, Mjaavatten O, et al. Performance of super-SILAC based quantitative proteomics for comparison of different acute myeloid leukemia (AML) cell lines. Proteomics. 2014;14(17–18):1971–1976.
   PubMed Web of Science ®Google Scholar
• Kaufmann SH, Steensma DP. On the TRAIL of a new therapy for leukemia. Leukemia. 2005;19(12):2195–2202.
   PubMed Web of Science ®Google Scholar
• Zhe N, Chen S, Zhou Z, et al. HIF-1alpha inhibition by 2-methoxyestradiol induces cell death via activation of the mitochondrial apoptotic pathway in acute myeloid leukemia. Cancer Biol Ther. 2016;17(6):625–634.
   PubMed Web of Science ®Google Scholar
• Vukovic M, Guitart AV, Sepulveda C, et al. Hif-1alpha and Hif-2alpha synergize to suppress AML development but are dispensable for disease maintenance. J Exp Med. 2015;212(13):2223–2234.
   PubMed Web of Science ®Google Scholar
• Folkerts H, Hilgendorf S, Wierenga ATJ, et al. Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. Cell Death Dis. 2017;8(7):e2927.
   PubMedGoogle Scholar
• Chen L, Guo P, Zhang Y, et al. Autophagy is an important event for low-dose cytarabine treatment in acute myeloid leukemia cells. Leuk Res. 2017;60:44–52.
   PubMed Web of Science ®Google Scholar
• Piya S, Kornblau SM, Ruvolo VR, et al. Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia. Blood. 2016;128(9):1260–1269.
   PubMed Web of Science ®Google Scholar
• Zhang S, Schneider LS, Vick B, et al. Anti-leukemic effects of the V-ATPase inhibitor Archazolid A. Oncotarget. 2015;6(41):43508–43528.
   PubMed Web of Science ®Google Scholar
• Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol. 2004;57(10):1009–1014.
   PubMed Web of Science ®Google Scholar
• Koshiji M, Huang LE. Dynamic balancing of the dual nature of HIF-1alpha for cell survival. Cell Cycle. 2004;3(7):853–854.
   PubMed Web of Science ®Google Scholar
• Sermeus A, Michiels C. Reciprocal influence of the p53 and the hypoxic pathways. Cell Death Dis. 2011;2:e164.
   PubMed Web of Science ®Google Scholar
• Fridman JS, Lowe SW. Control of apoptosis by p53. Oncogene. 2003;22(56):9030–9040.
   PubMed Web of Science ®Google Scholar
• Schneider LS, von Schwarzenberg K, Lehr T, et al. Vacuolar-ATPase inhibition blocks iron metabolism to mediate therapeutic effects in breast cancer. Cancer Res. 2015;75(14):2863–2874.
   PubMed Web of Science ®Google Scholar
• Zhang L, McGraw KL, Sallman DA, et al. The role of p53 in myelodysplastic syndromes and acute myeloid leukemia: molecular aspects and clinical implications. Leuk Lymphoma. 2017;58(8):1777–1790.
   Web of Science ®Google Scholar
• Bruserud Ø, Frostad S, Foss B. In vitro culture of acute myelogenous leukemia blasts: a comparison of four different culture media. J Hematother. 1999;8(1):63–73.
   PubMedGoogle Scholar
• Frostad S, Bjerknes R, Abrahamsen JF, et al. Insulin-like growth factor-1 (IGF-1) has a costimulatory effect on proliferation of committed progenitors derived from human umbilical cord CD34+ cells. Stem Cells (Dayton, Ohio). 1998;16(5):334–342.
   PubMed Web of Science ®Google Scholar
• Andrews NC. Molecular control of iron metabolism. Best practice & research. Clin Haematol. 2005;18(2):159–169.
   Google Scholar
• Roth M, Will B, Simkin G, et al. Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation. Blood. 2012;120(2):386–394.
   PubMed Web of Science ®Google Scholar
• Wang SJ, Gao C, Chen BA. Advancement of the study on iron metabolism and regulation in tumor cells. Chin J Cancer. 2010;29(4):451–455.
   PubMedGoogle Scholar
• Weiss G. Modification of iron regulation by the inflammatory response. Best practice & research. Clin Haematol. 2005;18(2):183–201.
   Google Scholar
• Torti SV, Torti FM. Iron and cancer: more ore to be mined. Nat Rev Cancer. 2013;13(5):342–355.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Ryningen A, Olsnes AM, et al. Subclassification of patients with acute myelogenous leukemia based on chemokine responsiveness and constitutive chemokine release by their leukemic cells. Haematologica. 2007;92(3):332–341.
   PubMed Web of Science ®Google Scholar
• Miller LD, Coffman LG, Chou JW, et al. An iron regulatory gene signature predicts outcome in breast cancer. Cancer Res. 2011;71(21):6728–6737.
   PubMed Web of Science ®Google Scholar
• Chirasani SR, Markovic DS, Synowitz M, et al. Transferrin-receptor-mediated iron accumulation controls proliferation and glutamate release in glioma cells. J Mol Med (Berl). 2009;87(2):153–167.
   PubMed Web of Science ®Google Scholar
• Peréz MJ, Fernandez N, Pasquini JM. Oligodendrocyte differentiation and signaling after transferrin internalization: a mechanism of action. Exp Neurol. 2013;248:262–274.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Ryningen A, Wergeland L, et al. Osteoblasts increase proliferation and release of pro-angiogenic interleukin 8 by native human acute myelogenous leukemia blasts. Haematologica. 2004;89(4):391–402.
   PubMed Web of Science ®Google Scholar
• Hatfield K, Ryningen A, Corbascio M, et al. Microvascular endothelial cells increase proliferation and inhibit apoptosis of native human acute myelogenous leukemia blasts. Int J Cancer. 2006;119(10):2313–2321.
   PubMed Web of Science ®Google Scholar
• Hindenburg AA, Gervasoni JE Jr, Krishna S, et al. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline-sensitive and -resistant HL-60 cells. Cancer Res. 1989;49(16):4607–4614.
   PubMed Web of Science ®Google Scholar
• Liao C, Hu B, Arno MJ, et al. Genomic screening in vivo reveals the role played by vacuolar H+ ATPase and cytosolic acidification in sensitivity to DNA-damaging agents such as cisplatin. Mol Pharmacol. 2007;71(2):416–425.
   PubMed Web of Science ®Google Scholar
• Marquardt D, Center MS. Involvement of vacuolar H(+)-adenosine triphosphatase activity in multidrug resistance in HL60 cells. J Natl Cancer Inst. 1991;83(15):1098–1102.
   PubMedGoogle Scholar
• Torigoe T, Izumi H, Ishiguchi H, et al. Enhanced expression of the human vacuolar H+-ATPase c subunit gene (ATP6L) in response to anticancer agents. J Biol Chem. 2002;277(39):36534–36543.
   PubMed Web of Science ®Google Scholar
• Saito T, Schlegel R, Andresson T, et al. Induction of cell transformation by mutated 16K vacuolar H+-atpase (ductin) is accompanied by down-regulation of gap junctional intercellular communication and translocation of connexin 43 in NIH3T3 cells. Oncogene. 1998;17(13):1673–1680.
   PubMed Web of Science ®Google Scholar
• Krysiak K, Gomez F, White BS, et al. Recurrent somatic mutations affecting B-cell receptor signaling pathway genes in follicular lymphoma. Blood. 2017;129(4):473–483.
   PubMed Web of Science ®Google Scholar
• Okosun J, Wolfson RL, Wang J, et al. Recurrent mTORC1-activating RRAGC mutations in follicular lymphoma. Nat Genet. 2016;48(2):183–188.
   PubMed Web of Science ®Google Scholar
• Gottlieb RA, Giesing HA, Zhu JY, et al. Cell acidification in apoptosis: granulocyte colony-stimulating factor delays programmed cell death in neutrophils by up-regulating the vacuolar H(+)-ATPase. Proc Natl Acad Sci U S A. 1995;92(13):5965–5968.
   PubMed Web of Science ®Google Scholar
• Ishisaki A, Hashimoto S, Amagasa T, et al. Caspase-3 activation during the process of apoptosis induced by a vacuolar type H(+)-ATPase inhibitor. Biol Cell. 1999;91(7):507–513.
   PubMed Web of Science ®Google Scholar
• Karwatowska-Prokopczuk E, Nordberg JA, Li HL, et al. Effect of vacuolar proton ATPase on pHi, Ca2+, and apoptosis in neonatal cardiomyocytes during metabolic inhibition/recovery. Circ Res. 1998;82(11):1139–1144.
   PubMed Web of Science ®Google Scholar
• Neri D, Supuran CT. Interfering with pH regulation in tumours as a therapeutic strategy. Nat Rev Drug Discov. 2011;10(10):767–777.
   PubMed Web of Science ®Google Scholar
• Hagland H, Nikolaisen J, Hodneland LI, et al. Targeting mitochondria in the treatment of human cancer: a coordinated attack against cancer cell energy metabolism and signalling. Expert Opin Ther Targets. 2007;11(8):1055–1069.
   PubMed Web of Science ®Google Scholar
• Luciani F, Spada M, De Milito A, et al. Effect of proton pump inhibitor pretreatment on resistance of solid tumors to cytotoxic drugs. J Natl Cancer Inst. 2004;96(22):1702–1713.
   PubMed Web of Science ®Google Scholar
• Hendrix A, Sormunen R, Westbroek W, et al. Vacuolar H+ ATPase expression and activity is required for Rab27B-dependent invasive growth and metastasis of breast cancer. Int J Cancer. 2013;133(4):843–854.
   PubMed Web of Science ®Google Scholar
• Buechling T, Bartscherer K, Ohkawara B, et al. Wnt/Frizzled signaling requires dPRR, the Drosophila homolog of the prorenin receptor. Curr Biol. 2010;20(14):1263–1268.
   PubMed Web of Science ®Google Scholar
• Chen SH, Bubb MR, Yarmola EG, et al. Vacuolar H+-ATPase binding to microfilaments: regulation in response to phosphatidylinositol 3-kinase activity and detailed characterization of the actin-binding site in subunit B. J Biol Chem. 2004;279(9):7988–7998.
   PubMed Web of Science ®Google Scholar
• Mauvezin C, Neufeld TP. Bafilomycin A1 disrupts autophagic flux by inhibiting both V-ATPase-dependent acidification and Ca-P60A/SERCA-dependent autophagosome-lysosome fusion. Autophagy. 2015;11(8):1437–1438.
   PubMed Web of Science ®Google Scholar
• Liberman R, Bond S, Shainheit MG, et al. Regulated assembly of vacuolar ATPase is increased during cluster disruption-induced maturation of dendritic cells through a phosphatidylinositol 3-kinase/mTOR-dependent pathway. J Biol Chem. 2014;289(3):1355–1363.
   PubMed Web of Science ®Google Scholar
• Thomas L, Rao Z, Gerstmeier J, et al. Selective upregulation of TNFalpha expression in classically-activated human monocyte-derived macrophages (M1) through pharmacological interference with V-ATPase. Biochem Pharmacol. 2017;130:71–82.
   PubMed Web of Science ®Google Scholar
• Scherer O, Steinmetz H, Kaether C, et al. Targeting V-ATPase in primary human monocytes by archazolid potently represses the classical secretion of cytokines due to accumulation at the endoplasmic reticulum. Biochem Pharmacol. 2014;91(4):490–500.
   PubMed Web of Science ®Google Scholar
• Hatfield KJ, Olsnes AM, Gjertsen BT, et al. Antiangiogenic therapy in acute myelogenous leukemia: targeting of vascular endothelial growth factor and interleukin 8 as possible antileukemic strategies. Curr Cancer Drug Targets. 2005;5(4):229–248.
   PubMed Web of Science ®Google Scholar
• Reikvam H, Hatfield KJ, Fredly H, et al. The angioregulatory cytokine network in human acute myeloid leukemia - from leukemogenesis via remission induction to stem cell transplantation. Eur Cytokine Netw. 2012;23(4):140–153.
   PubMed Web of Science ®Google Scholar
• Rath S, Liebl J, Furst R, et al. Regulation of endothelial signaling and migration by v-ATPase. Angiogenesis. 2014;17(3):587–601.
   PubMed Web of Science ®Google Scholar
• Ehninger A, Trumpp A. The bone marrow stem cell niche grows up: mesenchymal stem cells and macrophages move in. J Exp Med. 2011;208(3):421–428.
   PubMed Web of Science ®Google Scholar
• Sennoune SR, Arutunyan A, Del Rosario C, et al. V-ATPase regulates communication between microvascular endothelial cells and metastatic cells. Cell Mol Biol (Noisy-Le-Grand). 2014;60(1):19–25.
   PubMed Web of Science ®Google Scholar
• Di Pompo G, Lemma S, Canti L, et al. Intratumoral acidosis fosters cancer-induced bone pain through the activation of the mesenchymal tumor-associated stroma in bone metastasis from breast carcinoma. Oncotarget. 2017;8(33):54478–54496.
   PubMedGoogle Scholar
• Chen X, Wang Z, Duan N, et al. Osteoblast-osteoclast interactions. Connect Tissue Res. 2017;1–9. doi: 10.1080/03008207.2017.1290085. [Epub ahead of print]
   Google Scholar
• Sorensen MG, Henriksen K, Neutzsky-Wulff AV, et al. Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption. J Bone Miner Res. 2007;22(10):1640–1648.
   PubMed Web of Science ®Google Scholar
• Bruserud Ø, Foss B, Petersen H. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L). Eur Cytokine Netw. 2001;12(2):231–238.
   PubMed Web of Science ®Google Scholar
• Kaneko K, Ohba K, Hirose T, et al. Expression of (Pro)renin receptor during rapamycin-induced erythropoiesis in K562 erythroleukemia cells and its possible dual actions on erythropoiesis. Tohoku J Exp Med. 2017;241(1):35–43.
   PubMed Web of Science ®Google Scholar